Finanzwire Finanzwire
Basculer en Français
9546 Companies
188145 Keywords
120041 Articles
100501 Press releases
Headlines Articles Press releases Dr. Falk Pharma GmbH Remove
  1. Home
  2. Companies
  3. Dr. Falk Pharma GmbH
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 10/29/2024 at 13:05, 1 year 1 month ago

    Dr. Falk Pharma Acquires Kynos Therapeutics, Enhancing Portfolio in Inflammatory Diseases

    Inflammatory Diseases Dr. Falk Pharma Kynos Therapeutics Acute Pancreatitis KNS366
  • PRESS RELEASE

    published on 10/29/2024 at 13:00, 1 year 1 month ago

    Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio

    Dr. Falk Pharma GmbH acquires Kynos Therapeutics Ltd., focusing on inflammatory disease treatments. KNS366, a novel enzyme inhibitor, shows promise in clinical trials for acute pancreatitis
    Inflammatory Diseases Dr. Falk Pharma Kynos Therapeutics Acute Pancreatitis KNS366
    Logo of Dr. Falk Pharma GmbH
Accesswire
  • Published on 12/17/2025 at 15:00, 6 hours 36 minutes ago

    BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations

  • Published on 12/17/2025 at 14:00, 7 hours 36 minutes ago

    UniDoc Completes H3 Health Cube Installation in Italy

  • Published on 12/17/2025 at 13:35, 8 hours 1 minute ago

    Silver X Mining Announces Grant of Incentive Stock Options and Restricted Share Units

  • Published on 12/17/2025 at 13:15, 8 hours 21 minutes ago

    Aclara Wins UN Global Compact Award for Its Contribution to Local Employment and Suppliers

  • Published on 12/17/2025 at 13:00, 8 hours 36 minutes ago

    Gold Terra Provides a Summary of 2025 Achievements and 2026 Plan

View all ACCESSWIRE
EQS Group
  • Published on 12/17/2025 at 21:22, 14 minutes ago

    EQS-Adhoc: DATAGROUP SE: DATAGROUP SE Management Board plans dividend of EUR 0.04 per share

  • Published on 12/17/2025 at 20:12, 1 hour 24 minutes ago

    EQS-Adhoc: Rheinmetall AG: Executive Board decides to sell activities of the civil division Power Systems – Target is sale in the first quarter of 2026; update of outlook for continuing operation

  • Published on 12/17/2025 at 19:39, 1 hour 56 minutes ago

    Avolta awarded Shanghai Pudong International Airport concession, marking a first-in-a-generation duty-free win for an international operator in mainland China

  • Published on 12/17/2025 at 19:10, 2 hours 26 minutes ago

    Holand Automotive Group Announces the sale of Ferrari Rancho Mirage to Lapis Automotive Group

  • Published on 12/17/2025 at 18:39, 2 hours 57 minutes ago

    EQS-Adhoc: centrotherm international AG: Centrotherm AcquiCo AG submits request for the squeeze-out of minority shareholders of centrotherm international AG

View all EQS
Les Echos
  • Published on 12/17/2025 at 20:39, 57 minutes ago

    Aeroports de Paris SA | 2026 Airport charges in Paris

  • Published on 12/17/2025 at 19:30, 2 hours 6 minutes ago

    Change in the composition of the Board

  • Published on 12/17/2025 at 18:00, 3 hours 36 minutes ago

    Outstanding Shares and Voting Rights Statement at 30 November 2025

  • Published on 12/17/2025 at 17:51, 3 hours 45 minutes ago

    Mr.Bricolage: Completion of the simplification of the Mr.Bricolage Group’s shareholding structure

  • Published on 12/17/2025 at 17:50, 3 hours 46 minutes ago

    The Council of Paris approves the selection of Dalkia/Eiffage/RATP Solutions Ville consortium for Paris district heating network concession renewal.

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2025 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy